Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yulong Eco-Materials Limited (YECO)
Cheyenne, WY, US
EV Biologics, Inc. is a biotechnology enterprise focused on the commercial advancement of extracellular vesicles (EVs), utilizing them as biological agents for diagnostic and therapeutic applications. The company capitalizes on its proprietary, versatile EV platform to engineer innovative vaccines, treatments, and potential cures. Beyond EVs, it also dedicates efforts to cultivating human mesenchymal and other stem cells, as well as various cell-derived products, to address the needs of the cosmetic and biopharmaceutical industries. Founded in 2011, the firm was originally known as Yulong Eco-Materials Limited until its rebranding to EV Biologics, Inc. in August 2020, and it operates from its headquarters in Cheyenne, Wyoming.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -70.00% | -81.71% | -85.00% | -81.50% | -82.56% | -97.87% | -99.67% | -99.54% | -99.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+264.8% ★
-
EPS growth Biotechnology: +29.7%+75.7% ★ Q2'25: +75.9% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-70.9%
-
EBIT margin Biotechnology: +0.0%-167.4%
-
ROIC Biotechnology: -16.1%— Q2'25: +38.6% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q2'25: +0.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.03× Q2'25: -8.06× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zhu | 4.87M | 41.04% | 4.87M | — | 4.87M | 10.00 | IN | Republic of China | 2015-08-19 | ↗ |
| 2 | Wenge Du | 1.73M | 14.60% | 1.73M | — | 1.73M | 10.00 | IN | People’s Republic of China | 2015-11-25 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-01-31 | McKinney Daniel S | Director / Officer / 10% Owner | J-Other | D | Common Stock | 25,000,000 | 0.00 | — | 1,900 | — | ↗ |
| 2018-12-18 | McKinney Daniel S | 10% Owner | J-Other | A | Common Stock | 900 | 1.34 | 1.2K | 25,001,900 | — | ↗ |
| 2018-11-27 | McKinney Daniel S | 10% Owner | J-Other | A | Common Stock | 200 | 5.99 | 1.2K | 25,001,000 | — | ↗ |
| 2018-11-17 | McKinney Daniel S | 10% Owner | J-Other | A | Common Stock | 300 | 5.07 | 1.5K | 25,000,800 | — | ↗ |
| 2018-11-08 | McKinney Daniel S | 10% Owner | J-Other | A | Common Stock | 200 | 6.09 | 1.2K | 25,000,500 | — | ↗ |
| 2018-10-24 | McKinney Daniel S | 10% Owner | J-Other | A | common stock | 300 | 5.95 | 1.8K | 25,000,300 | — | ↗ |
| 2018-10-17 | McKinney Daniel S | 10% Owner | J-Other | A | common stock | 25,000,000 | 2.00 | 50.00M | 25,000,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Daniel S. McKinney | Founder, Chairman & Chief Executive Officer | — | male |
| Eric Jeperson | Chief Financial Officer | — | — |
| William Bossung | Corporate Finance Director & Corporate Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for YECO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
